Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

NXL US Equity

Nexalin Technology, Inc.Health Care · Electromedical & Electrotherapeutic Apparatus · CIK 1527352 · FY ends Dec 31
$0.33
-0.00 (-0.99%)
USD · as of 2026-08-19 · marketstack
1 registered study · 1 active

Studies where NXL is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.

1 interventional

Held by 2 tracked-famous managers (CITADEL ADVISORS LLC, JANE STREET GROUP, LLC) · FINRA short interest 1.5 days to cover (settled 2026-07-31) · government filings 180d: none disclosed

StudyPhaseStatusInterventionsConditionsEnrollmentPrimary completionReadout inUpdated
HALO Clarity™ Cranial Alternating Current Stimulation Therapy for Adults With Moderate-to-Severe InsomniaNCT07659366Change in Insomnia Severity Index (ISI) Total Score at Week 4Randomized · Triple-masked · TreatmentNot applicableNot yet recruitingDevice: Transcranial alternating current stimulatorModerate to Severe Insomnia1602027-07-01in 315 d2026-06-23

Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.

Source: ClinicalTrials.gov, retrieved 2026-08-19